- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03296787
A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954
A Phase 1, Open-Label, Parallel Group Trial to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single Intravenous Dose of TAK-954
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The drug being tested in this study is called TAK-954. This study will evaluate the effect of varying degrees of renal function on the PK of TAK-954 following single-dose IV administration and to investigate the impact of hemodialysis on the PK of single IV doses of TAK-954.
The study will enroll approximately up to 40 participants. Participants will be enrolled in one of the 5 treatment groups based on their renal impairment which will be determined based on Cockcroft and Gault (CG) equation as follows:
- Group A TAK-954 0.2 mg: Healthy Participants
- Group B TAK-954 0.2 mg: Mild Renal Impairment
- Group C TAK-954 0.2 mg: Moderate Renal Impairment
- Group D TAK-954 0.2 mg: Severe Renal Impairment or End-stage Renal Disease (ESRD) Without Hemodialysis
- Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD) With Hemodialysis
All participants in groups A to D will receive a single dose of TAK-954 and two single doses in Group E.
Enrollment in Group B (Mild) and Group E (ESRD requiring dialysis) will be based on assessment of safety and available PK data from Group C and Group D respectively.
This multi-center trial will be conducted in Czech Republic and Hungary. The overall time to participate in this study is approximately 8 weeks. Participants in Groups A to D will remain confined to clinic for 3 days. For both treatments, participants in Group E requiring dialysis will remain confined to clinic for 3 days. All participants will make a final visit to the clinic 10-14 days after receiving their last dose for a follow-up assessment.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- All participants: Male and female participants (non-childbearing potential) who are aged 18 to 75 years, inclusive, with a body mass index (BMI) between 18 to 35 kilogram per square meter (kg/m^2).
- Group A: As much as possible, the healthy participants with normal renal function (creatinine clearance [CLcr] greater than or equal to [>=] 90 milliliter per minute [mL/min]) should be comparable to participants with renal impairment with respect to median age and weight (approximately 50 percent [%] of healthy participants on each side of the median age and weight of currently enrolled renally-impaired participants grouped together), sex, and race. This will be decided by the investigators in discussion with Takeda.
Groups B to E: Participants who have stable RI, defined as no clinically significant change in disease status, as documented by the participant's most recent CLcr assessment; serum creatinine must not vary more than approximately 30% from Screening to Day -1 to confirm stable disease. Participants should also be in good health commensurate with their renal status.
- Group B: Participants with mild RI (CLcr 60 to less than [<] 90 mL/min).
- Group C: Participants with moderate RI (CLcr 30 to <60 mL/min).
- Group D: Participants with severe RI or ESRD but not requiring dialysis (CLcr <30 mL/min).
- Group E: Participants with ESRD requiring dialysis (<15 mL/min requiring hemodialysis at least 3 times/week, and having been on the same dialysis treatment regimen for at least 1 month before trial entry).
- Participants should be on a stable drug regimen defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) before dosing with TAK-954.
Exclusion Criteria:
All participants:
- Are renal allograft recipients within 1 year of screening.
- Have a history of gastrointestinal (GI) motility disorder or intestinal obstruction.
- Have urinary incontinence without catheterization.
- Group A: Participants who, in the discretion of the investigator, have a history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases will be excluded from the trial.
Groups B to E:
- Receive dialysis other than intermittent dialysis (except Group E).
- Have renal disease secondary to hepatic disease (hepatorenal syndrome).
- At the discretion of the investigators, have any significant hepatic, cardiac, or pulmonary disease or participants who are clinically nephrotic.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Group A TAK-954 0.2 mg: Healthy Participants
Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
|
TAK-954 intraveneuze infusie.
|
Experimenteel: Group B TAK-954 0.2 mg: Mild Renal Impairment
Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
|
TAK-954 intraveneuze infusie.
|
Experimenteel: Group C TAK-954 0.2 mg: Moderate Renal Impairment
Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
|
TAK-954 intraveneuze infusie.
|
Experimenteel: Group D TAK-954 0.2 mg: Severe Renal Impairment
Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
|
TAK-954 intraveneuze infusie.
|
Experimenteel: Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD)
Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.
|
TAK-954 intraveneuze infusie.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Groups A, C and D; Cmax: Maximum Observed Plasma Concentration for TAK-954 (Total and Free)
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Groups A, C and D; AUC(0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Post-dose for TAK-954 (Free and Total)
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 72 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 72 hours) post-infusion
|
Groups A, C and D; AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954 (Free and Total)
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Groups A, C and D; AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 (Free and Total)
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Groups A, C and D; Ae: Amount of TAK-954 Excreted in Urine
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 1
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 2
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Groups A, C and D; Fe: Fraction of TAK-954 Excreted in Urine
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 1
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 2
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Groups A, C and D; CLR: Renal Clearance for TAK-954
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; CLR: Renal Clearance for TAK-954 in Period 1
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; CLR: Renal Clearance for TAK-954 in Period 2
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; CLD: Clearance of Dialysate for TAK-954 in Period 2
Tijdsspanne: Day 1 pre-infusion and at multiple time points (up to 4 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 4 hours) post-infusion
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- TAK-954-1007
- U1111-1196-9206 (Register-ID: WHO)
- 2017-000715-16 (EudraCT-nummer)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Nierfunctiestoornis
-
Postgraduate Institute of Medical Education and...VoltooidType 1 HEPATO RENAL SYNDROOM (HRS)Indië
-
Charite University, Berlin, GermanyGerman Federal Ministry of Education and ResearchOnbekendChronische afasie na een beroerte | Anomie (Word-retrieval Impairment)Duitsland
-
Bristol-Myers SquibbVoltooidTrombose | Nierfunctiestoornis | Factor XI | ESRD (End-Stage Renal Disease)Verenigde Staten
-
Children's Oncology GroupNational Cancer Institute (NCI)VoltooidHeldercellig niercelcarcinoom | Stadium III niercelkanker | Stadium IV niercelkanker | Heldercellig sarcoom van de nier | Papillair niercelcarcinoom | Rhabdoïde tumor van de nier | Stadium I niercelkanker | Niercelcarcinoom bij kinderen | Stadium II niercelkanker | Stadium I Renal Wilms-tumor | Stadium II... en andere voorwaardenVerenigde Staten, Canada, Australië, Nieuw-Zeeland, Puerto Rico
Klinische onderzoeken op TAK-954
-
TakedaTakeda Development Center Americas, Inc.VoltooidPostoperatieve gastro-intestinale disfunctieVerenigde Staten, Duitsland
-
Millennium Pharmaceuticals, Inc.VoltooidGezonde vrijwilligersVerenigde Staten
-
TakedaVoltooidGezonde vrijwilligers | LeverfunctiestoornisTsjechië, Slowakije
-
TakedaVoltooidDiabetische gastroparese | Idiopathische gastropareseVerenigde Staten
-
AbbVieInfinity Pharmaceuticals, Inc.Voltooid
-
TakedaVoltooid
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WervingHPV | Verwante maligniteit | Verwant carcinoomVerenigde Staten
-
TakedaVoltooid
-
TakedaVoltooid
-
TakedaBeëindigdAandachtstekortstoornis met hyperactiviteitVerenigde Staten